Persistence of both cords nine months post double cord blood transplantation for juvenile myelomonocytic leukaemia
To the Editor: Single donor cord dominance after double-cord blood transplant (DCBT) is common. 1 We report the case of a 2-year-old boy who had persistence of both cords 9-months post-DCBT done for juvenile myelomonocytic leukaemia (JMML). Both cord units were 4/6 match at HLA loci with respect to the recipient and 6/6 with each other (Table 1). The combined CD34 cell count of the grafts was 2.69 · 10 5 /kg of recipient body weight. The cords were infused intravenously in a sequential manner post myeloablative conditioning with busulphan (16 mg/kg), cyclophosphamide (120 mg/kg) and melphalan (140 mg/m 2 ). Graft-versus-host disease (GVHD) prophylaxis comprised ATG, cyclosporine and prednisolone. Neutrophil and platelet engraftment occurred on days +15 and 49 post-transplant respectively. The patient developed grade-III acute skin and gut GVHD which responded to prednisolone 2 mg/kg/day and topical medications. This later evolved into chronic skin rash and diarrhoea which were managed with local and systemic steroids and imatinib mesylate. Patient also had cytomegalovirus reactivation which was resistant to ganciclovir but responded well to intravenous foscarnet. His blood group changed to that of donor cord 2 initially and later to cord 1 ( Table 2 ). The peripheral blood chimerism showed persistence of both units on day +268. The results of his engraftment studies are shown in Fig 1. Gradually his oral steroids could be tapered off by day +180. However, the patient continued on cyclosporine and oral budesonide. Presently, the child is 300 days post-transplant with sustained remission and donor stem cell engraftment with mixed chimerism (64% cord-1 and 36% cord-2). However, he has developed acute skin and gut GVHD features again and has required reintroduction of steroids. There is paucity of data on DCBT in children with JMML. Kang et al performed DCBT in 61 children with leukaemia and other haematological and metabolic disorders of which three patients were JMML.
2 Two out of these three patients had spontaneous autologous recovery.
It has been observed that after a period of transient engraftment of both cords in DCBT, one cord may become dominant which may be as early as d+21 post-transplant. In a study by Milano et al, out of 46 patients undergoing myeloablative DCBT all except one patient had complete contribution from a single unit (as defined !95% chimerism), at a median time of 14 days (IQR, 14-21 days). The only patient with persistent contribution from both units, still present at one year post transplantation, received a treosulfan-based conditioning regimen and 2 6/6 HLA-matched units. 1 Factors which lead to dominance of one cord are not completely understood. It is postulated that the cord units with higher cell viability (>75%) are more likely to engraft. 3 Other authors have proposed that the difference of viable cell count between the two cord units of more than 15% is associated with better engraftment secondary to immunological interaction between the two units. 2 Most authors report single unit dominance but sustained mixed chimerism as in our case is also known to occur.
1,2 Avery et al analysed the biology of engraftment in 84 DCBTs and found that factors predictive of dominance were a higher CD 34 + and CD 3 + cell dose 4 similar to a study of Milano et al. 1 HLA mismatch between the cord units was not found to influence sustained engraftment. However, if both cords are a 6/6 match to each other as in our case or one in the series of Milano et al. 1 , then mixed chimerism is highly likely. A potential advantage of DCBT is a lower relapse rate owing to greater graft versus leukaemia effect 5 but GVHD may be a significant adverse effect as seen in our patient who continues to have diarrhoea.
Although dominant cord engraftment post DCBT is common, it is not, however, a rule. Persistence of both cord units is more likely if these are a 6/6 match to each other and may lead to delayed acute GVHD. 
